This HTML5 document contains 170 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n9http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q37119406
rdf:type
wikibase:Item
schema:description
2008年学术文章 2008年學術文章 vetenskaplig artikel vědecký článek artigo científico (publicado na 2008) ২০০৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2008年の論文 2008年學術文章 գիտական հոդված artykuł naukowy scientific article published on 15 September 2008 научни чланак vitenskapelig artikkel 2008年学术文章 scienca artikolo vedecký článok naučni članak სამეცნიერო სტატია article scientifique publié en 2008 videnskabelig artikel (udgivet 2008) mokslinis straipsnis article scientific 2008年学术文章 artigo científico 2008年學術文章 мақолаи илмӣ vitskapeleg artikkel wetenschappelijk artikel tudományos cikk บทความทางวิทยาศาสตร์ наукова стаття, опублікована у вересні 2008 teaduslik artikkel научни чланак artículu científicu espublizáu en 2008 научна статия bài báo khoa học artículo científico publicado en 2008 2008年学术文章 2008년 논문 artikull shkencor wissenschaftlicher Artikel مقالة علمية نشرت في 15 سبتمبر 2008 bilimsel makale 2008年學術文章 2008年學術文章 artigo científico (publicado na 2008) 2008年学术文章 מאמר מדעי мақолаи илмӣ article científic tieteellinen artikkeli επιστημονικό άρθρο 2008年學術文章 articolo scientifico articol științific научная статья 2008 nî lūn-bûn مقالهٔ علمی artikulong pang-agham سائنسی مضمون
p:P577
wds:Q37119406-E09E1878-B598-4136-9E02-6853E010B2AE
wdt:P577
2008-09-15T00:00:00Z
p:P407
wds:Q37119406-6EDF3FC5-263D-45EC-8739-70ECFA5DA445
wdt:P407
wd:Q1860
p:P2860
wds:Q37119406-857A55DB-BBCB-4556-A8E7-9F307987686A wds:Q37119406-85898587-D7DA-4FFC-8189-E2124461D2BE wds:Q37119406-1F142868-2B4E-4B6D-B13A-3443D9765CC5 wds:Q37119406-3F4AD5DB-4F90-4812-B7C7-8433F828F24A wds:Q37119406-0EAB0DD6-9D15-42F1-970D-29E45BB72BC1 wds:Q37119406-1670F26D-FBA1-4A12-8FA3-A5CDE4D98677 wds:Q37119406-1C5E9F39-2EAB-4529-9450-36FBFDDAA58B wds:Q37119406-508DCD1A-FFFD-401A-9120-2E3E8E1BE3F8 wds:Q37119406-5976B45A-674E-4901-81BE-5F71D78312BA wds:Q37119406-5D612A8C-36BD-4BEC-85D9-8ECE47996785 wds:Q37119406-6284ED6E-AD07-48FA-888C-F208845BFE59 wds:Q37119406-CA03E067-59D7-47AE-8389-6C2D976D7798 wds:Q37119406-CB554612-BE24-4FF3-ACF9-21A829403EE8 wds:Q37119406-B892D9FF-C4A6-4EB5-9907-7AC8E91743D1 wds:Q37119406-BD81AECC-5F4C-419C-B7CB-193EEA382D2A wds:Q37119406-C28B46C4-74D4-4E54-938C-4A03F0B8889F wds:Q37119406-FCC9E221-6866-4DF4-8EC7-85AE29D70BCB wds:Q37119406-F26ECA9C-0DA7-4F36-B559-C073674C5698 wds:Q37119406-F4F51821-F468-477F-A440-1B035A66A565 wds:Q37119406-0447C9B7-2E93-4684-93F4-AAFCA24BFDA2 wds:Q37119406-083988BA-D34E-4A9C-990D-EA70490DA0F0 wds:Q37119406-0B7464DA-DC2A-4915-8F75-5A88DB03796C wds:Q37119406-7A425F48-ADE5-4F4C-A74B-E3BF32AB6F20 wds:Q37119406-817BC2EF-88F0-41A7-8D8E-11541BC79DB8 wds:Q37119406-6CF263FE-C025-4590-9483-86D9106F741E wds:Q37119406-9CF2FAC4-F8B8-496D-98B4-51B5DC789274
wdt:P2860
wd:Q35800541 wd:Q36217986 wd:Q51936030 wd:Q54057203 wd:Q33373325 wd:Q27860904 wd:Q29614276 wd:Q71381861 wd:Q46871053 wd:Q29619344 wd:Q40832627 wd:Q24816432 wd:Q41328347 wd:Q34436986 wd:Q38467726 wd:Q33716127 wd:Q40460294 wd:Q73838278 wd:Q33376286 wd:Q50600933 wd:Q57424632 wd:Q80557811 wd:Q40174177 wd:Q74525541 wd:Q40551071 wd:Q43658492
p:P2093
wds:Q37119406-C6B6642C-FAA9-4B85-B28A-EFF864E27A56 wds:Q37119406-E6B1D83B-45D9-4941-8A86-817C6EF24C58 wds:Q37119406-2299ECEA-885A-418E-8EC3-2C6055D06628 wds:Q37119406-47640AFF-43F1-460A-89EF-18EEF4266D34 wds:Q37119406-49984170-5822-40D6-BDBC-730242F0DA68 wds:Q37119406-6740354B-57B3-46F3-8974-FE1744F5A1C6 wds:Q37119406-7178D2D0-8952-4528-B4E8-5E941DC17E96 wds:Q37119406-A45DDC13-918A-4325-8EBE-F198F0EBA4CF wds:Q37119406-9ACD06B3-C412-43CD-9FF8-05EFEFE933CA
wdt:P2093
Stephan D Voss Janet E Dancey Ashish M Ingle Regina I Jakacki Marta Hamilton Jean Tersak Peter C Adamson Mark D Krailo Richard J Gilbertson
rdfs:label
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study
skos:prefLabel
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
schema:name
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study
p:P50
wds:Q37119406-D46D5484-C205-4D32-B6CC-FFC22C47888A
wdt:P50
wd:Q73565675
p:P1476
wds:Q37119406-C45EC326-35E8-4E95-81E1-EF10CF7DEE1A
wdt:P1476
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study
p:P304
wds:Q37119406-3F5BBBC0-C003-4564-B74C-29E9128E1C06
wdt:P304
4921-4927
p:P31
wds:Q37119406-423E73B8-7203-477A-A7FC-E4283D67A6CA
wdt:P31
wd:Q13442814
p:P921
wds:Q37119406-629F1D42-A7E9-4EEC-8487-BD2FADED031A
wdt:P921
wd:Q425088
p:P698
wds:Q37119406-0364BA39-F804-47BA-826A-58271D8EAA09
wdtn:P698
n12:18794549
wdt:P698
18794549
p:P1433
wds:Q37119406-8259D53E-0EA6-4F28-BAC9-7F2F5ABA36A3
wdt:P1433
wd:Q400292
p:P433
wds:Q37119406-1F091333-992F-4818-A495-C19485062D39
p:P478
wds:Q37119406-34DE4AD5-97AB-4B72-A568-DC0A5469EE89
wdt:P433
30
wdt:P478
26
p:P356
wds:Q37119406-88F733CD-557B-4708-8946-35E05F5ECF6F
wdtn:P356
n9:JCO.2007.15.2306
wdt:P356
10.1200/JCO.2007.15.2306
p:P4510
wds:Q37119406-74EA3EFB-1E1E-4654-8C62-744263C43413
wdt:P4510
wd:Q1659584
p:P932
wds:Q37119406-ACCDEE5B-D9F7-41A2-870E-236B60B4476D
wdt:P932
2652086